The Search for Antidepressants - An Integrative View of Drug Discovery

Book Series: Frontiers in Drug Discovery

Volume 2


Andre F. Carvalho, Gislaine Zilli Reus, João Luciano de Quevedo

DOI: 10.2174/97816810847321170201
eISBN: 978-1-68108-473-2, 2017
ISBN: 978-1-68108-474-9
ISSN: 2542-7350 (Print)
ISSN: 2214-6210 (Online)

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disabi...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology

Novel Non-Monoaminergic Antidepressants: Focus on Neuropeptides

- Pp. 242-255 (14)

Donatella Marazziti, Federico Mucci, Stefano Baroni and Liliana Dell`Osso


Major depressive disorder (MDD) is a common illness representing a social problem worldwide, that is predicted to become the second cause of disability in 2020 by the World Health Organization (WHO), with a heavy economic burden for the western societies. The discovery of the first-generation antidepressants, i.e., monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), followed by selective serotonin reuptake inhibitors (SSRIs), dual-acting serotonin/norepinephrine reuptake inhibitors (SNRIs) and a few others, improved significantly the treatment and the prognosis of MDD, besides promoting the investigation of its possible biological mechanisms. However, the long latency of therapeutic effect, the presence of relevant side effects and the treatment’s resistance are still major problems in MDD management. For those reasons, the pharmacological treatment of MDD is still far from being satisfactory, without any significant paradigm shifts in the psychopharmacology of MDD occurring in the last decades. More recently, other mechanisms, besides monoamines’ modulation, have been explored in the attempt to discover novel and effective antidepressants. To date, a number of novel compounds acting on neuropeptide receptors have been developed and tested in both animals and humans with different results. In this chapter, we will provide a short overview of the main neuropeptides, from their biochemical and molecular characteristics to preclinical and clinical evidence in MDD.

Purchase Chapter  Book Details


5th Annual Pharmacon Asia

Webmaster Contact: Copyright © 2018 Bentham Science